Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03954717 · ClinicalTrials.gov registry record
Pilot Study Evaluating Functional and Wellness Outcomes of the Shepherd CAN DO MS Program
A clinical trial of Multiple Sclerosis, sponsored by Shepherd Center, Atlanta GA.
- Completed
- Registry status
- 111
- Enrollment target
- 1
- Study location
NCT03954717: Completed study of Multiple Sclerosis, sponsored by Shepherd Center, Atlanta GA.
NCT03954717 is a study of Multiple Sclerosis that has completed, run by Shepherd Center, Atlanta GA. The registered enrollment target is 111 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03954717, a study of Multiple Sclerosis, has completed, sponsored by Shepherd Center, Atlanta GA.
- COMPLETED
- Registry status
- 111 participants
- Enrollment target
- 1
- Study location
Study Summary
The study evaluates the efficacy of the CAN DO Program for improving health, wellness, and quality of life in people with MS, and compares outcomes between people with MS who participate in the CAN DO Program to a control group of people with MS who do not participate in the CAN DO Program. The study also evaluates the impact of the CAN DO Program on support partners.
Primary Outcome
The extent to which participants demonstrate increased self-efficacy (the confidence in one's belief to undertake a task) to manage symptoms measured by the Multiple Sclerosis Self-Management Scale Revised (MSSM-R) Constructs measured: * Healthcare provider relationship \& communication * Treatment adherence/barriers * Social/family support * MS knowledge \& information * Health maintenance behavior 24 items, with score 1 (disagree completely) to 5 (agree completely) For some 1 is a positive o
Conditions Studied
Interventions
- BEHAVIORAL Shepherd CAN DO Program
Study Locations (1)
Georgia
- Shepherd Center - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2019-05-14 |
| Est. Completion | 2022-03-11 |
What the finished NCT03954717 record still lists
NCT03954717 is an observational study that tracks outcomes without assigning an intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Shepherd CAN DO Program is the first listed.
NCT03954717 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT03954717 about?
NCT03954717 is a clinical study titled "Pilot Study Evaluating Functional and Wellness Outcomes of the Shepherd CAN DO MS Program". The study evaluates the efficacy of the CAN DO Program for improving health, wellness, and quality of life in people with MS, and compares outcomes between people with MS who participate in the CAN DO Program to a control group of people with MS who do not participate in the CAN DO Program. The stud...
What is the current status of trial NCT03954717?
This trial is currently completed. The enrollment target is 111 participants. The study started on 2019-05-14. Estimated completion is 2022-03-11.
What conditions does trial NCT03954717 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT03954717?
The interventions under investigation include: Shepherd CAN DO Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT03954717?
This trial is sponsored by Shepherd Center, Atlanta GA, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03954717 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03954717's enrollment target sits among peer trials
111 123rd of 315 higher than 193 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03875716 · 111 participants · NA
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- NCT04693468 · 111 participants · Phase 1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- NCT05263050 · 111 participants · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- NCT05600842 · 111 participants
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI